BR112015013196A2 - combinations of a pi3k / akt inhibitor compound with a her3 / egfr inhibitor compound and methods of use - Google Patents

combinations of a pi3k / akt inhibitor compound with a her3 / egfr inhibitor compound and methods of use

Info

Publication number
BR112015013196A2
BR112015013196A2 BR112015013196-4A BR112015013196A BR112015013196A2 BR 112015013196 A2 BR112015013196 A2 BR 112015013196A2 BR 112015013196 A BR112015013196 A BR 112015013196A BR 112015013196 A2 BR112015013196 A2 BR 112015013196A2
Authority
BR
Brazil
Prior art keywords
gdc
combination
pharmaceutically acceptable
acceptable salt
cancer
Prior art date
Application number
BR112015013196-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Baselga Jose
Scaltriti Maurizio
Original Assignee
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation filed Critical The General Hospital Corporation
Publication of BR112015013196A2 publication Critical patent/BR112015013196A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015013196-4A 2012-12-07 2013-12-09 combinations of a pi3k / akt inhibitor compound with a her3 / egfr inhibitor compound and methods of use BR112015013196A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734796P 2012-12-07 2012-12-07
US61/734,796 2012-12-07
US201361888892P 2013-10-09 2013-10-09
US61/888,892 2013-10-09
PCT/US2013/073914 WO2014089570A1 (en) 2012-12-07 2013-12-09 Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder

Publications (1)

Publication Number Publication Date
BR112015013196A2 true BR112015013196A2 (en) 2018-02-06

Family

ID=49885413

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015013196-4A BR112015013196A2 (en) 2012-12-07 2013-12-09 combinations of a pi3k / akt inhibitor compound with a her3 / egfr inhibitor compound and methods of use

Country Status (11)

Country Link
US (1) US9566334B2 (enExample)
EP (1) EP2928488A1 (enExample)
JP (1) JP2016502974A (enExample)
KR (1) KR20150092760A (enExample)
CN (1) CN104968363A (enExample)
BR (1) BR112015013196A2 (enExample)
CA (1) CA2894153A1 (enExample)
HK (1) HK1211218A1 (enExample)
MX (1) MX2015007054A (enExample)
RU (1) RU2015127037A (enExample)
WO (1) WO2014089570A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015140573A (ru) * 2013-02-25 2017-03-30 Дженентек, Инк. Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
CN109789141B (zh) 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US7312243B1 (en) * 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
BRPI0816769A2 (pt) * 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
KR20150036824A (ko) * 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US8895001B2 (en) * 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
TR201815685T4 (tr) * 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
WO2012177925A1 (en) * 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
EP2780469A1 (en) * 2011-11-18 2014-09-24 Vanderbilt University Markers of triple-negative breast cancer and uses thereof
EP2788752B1 (en) * 2011-12-05 2018-10-03 Pierian Holdings, Inc. Method of therapy selection for patients with lung cancer

Also Published As

Publication number Publication date
RU2015127037A (ru) 2017-01-11
KR20150092760A (ko) 2015-08-13
CA2894153A1 (en) 2014-06-12
WO2014089570A1 (en) 2014-06-12
HK1211218A1 (en) 2016-05-20
US9566334B2 (en) 2017-02-14
EP2928488A1 (en) 2015-10-14
JP2016502974A (ja) 2016-02-01
US20150306216A1 (en) 2015-10-29
CN104968363A (zh) 2015-10-07
MX2015007054A (es) 2016-01-12

Similar Documents

Publication Publication Date Title
CN108024541B (zh) 用于治疗癌症的方法
TW202038957A (zh) 抗體-藥物結合物與激酶抑制劑之組合
CN105873440B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
JP2020147570A (ja) 抗ｈｅｒ２抗体−薬剤コンジュゲートと化学療法剤の併用及び使用方法
JP2023145689A (ja) Ｈｅｒ２陽性がんの処置
US9682082B2 (en) Combinations of AKT and MEK inhibitor compounds, and methods of use
WO2012155063A1 (en) Treating cancer with an hsp90 inhibitory compound
JP2017503842A (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
JP2019526559A (ja) 膵がん治療のための組み合わせ治療薬
JP7132848B2 (ja) 癌の治療のための合理的併用療法
WO2020128613A1 (en) Use of il-1beta binding antibodies
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
JP2015503568A (ja) トラスツズマブに不応性の乳癌の治療方法
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
EP4694891A1 (en) Dosage regimen for sotorasib/carboplatin/pemetrexed in cancer treatment
US9801840B1 (en) Pharmaceutical composition and use thereof
JP2022023033A (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use
EA039396B1 (ru) Лечение рака молочной железы с тройным негативным фенотипом ингибиторами tor-киназы

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]